- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: | |
Articles on Novo Nordisk A/S (NVO)
by latest | most commented
-
Big Pharma: Where's the Risk Management?
-
FDA Calendar Updates: Novo Nordisk, Eisai, Acura, King and Myriad Pharma
-
Preview from Europe: Stocks End Quarter with a Whimper
-
European Stocks in the News
-
How Bad Is Sanofi's Safety Scare?
-
ADA Meeting 2009: Novel Diabetes Therapies Presented
-
These European Nations Are in Worse Shape than the U.S.
-
The 30 Best U.S. Traded International Dividend Stocks
-
Emisphere: Improving Drug Delivery
-
What's in Store for Amylin and Biogen Idec's Shareholder Meetings?
-
Early Filing for Byetta: Will It Become a Blockbuster?
-
FDA Calendar Updates: Diabetes
-
Amylin's Pullback Is Unjustified
-
FDA Calendar Updates: Santarus, Cephalon, AstraZeneca, Dendreon, Gilead, Novo Nordisk
-
15 'Bathwater Babies' and 20 'Dogs with Fleas' for the Week
-
Which Diabetes Drugs Will Win Out?
-
Novo Nordisk Short Interest Increases 500% in March
-
Merck's Jumpin' Januvia Gets a Reprieve
-
Updates to FDA and Clinical Trial Calendars
-
Expect More REITs Stock Dividends
-
Will 2009 Be a Year for Pharma Currency Speculators?
-
Healthcare Reform, M&A Likely to Focus on Preventative Medicine
-
Hedge Fund Portfolio Tracking: Renaissance Technologies (Jim Simons), Q3 2008
-
New Scandinavian Nordic Region Index
-
New Index of Preventive Medicine Companies
-
Nine Pharma Predictions for 2009
-
China Biopharma News Back in the Spotlight
-
Big Pharma Steps Up China Investment
-
What Are Some of the Best Hedge Fund Managers Doing?
-
Novo Nordisk: Approval of New Diabetes Drug Is Further Postponed
-
China Biotech in Review: Earnings Week
-
Novo Nordisk Expands R&D Presence in China with New Manufacturing Plant
-
Bullish Outlook for Preventive Medicine Companies Reflected in New ETF
-
The Market Is Weak - Fast Money Recap (9/8/08)
-
AstraZeneca Gives FluMist Spray a Shot in the Arm
-
Four Drug Companies Vying for Diabetes Patients
-
NordiCaps Regional Stock Index: Tracking Scandinavia's Finest
-
Credit Suisse Healthier 15: Investors Get the Skinny on Fat Fighters
-
Diabetes Stocks Remain Healthy
-
Is Lilly and Amylin's Byetta Better?
-
ADA's 68th Scientific Sessions: A New Look at Insulin Therapy